A new collaboration with Alcon will drive development of adjustable PC IOLs, expanding innovation and market reach. Q2 revenue declined due to competitive trialing, prompting revised 2026 guidance and increased commercial investment. The product pipeline and clinical differentiation remain key growth drivers.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.